American "internet celebrity broker" Robinhood (HOOD.US) will pay $45 million to settle SEC charges.
The "Internet celebrity brokerage" Robinhood Markets (HOOD.US) has agreed to pay $45 million to settle charges by the SEC related to record-keeping, trade reporting, and other violations.
The U.S. Securities and Exchange Commission (SEC) stated on Monday that "internet-famous broker" Robinhood Markets (HOOD.US) has agreed to pay $45 million to settle charges by the SEC regarding its record-keeping, trade reporting, and other violations.
Regulators found that Robinhood Securities LLC and Robinhood Financial LLC violated numerous requirements, such as accurately reporting trade activity, timely submitting reports of suspicious activity, maintaining records, and complying with short-selling rules.
Robinhood has also become the latest brokerage firm to admit to violations, as employees used instant messaging applications and other "off-channel" communication platforms to retain work-related communications.
The company acknowledged these mistakes and flawed trade data. Regulators also found that Robinhood failed to adequately address cybersecurity risks. Robinhood's general counsel, Lucas Moskowitz, stated that the company is pleased to have resolved these issues.
Moskowitz said in a statement, "We have the capability to continue leading the industry in developing innovative products and services that customers want and need. We look forward to working with the SEC under the leadership of the new U.S. administration."
Related Articles

HK Stock Market Move | MMG(01208) closing price rose more than 7%, operations at the Las Bambas mine area are stable, institutions raise full-year copper production guidance.

Tonghua Dongbao Pharmaceutical (600867.SH): Recombinant Human Insulin Injection receives foreign drug registration certificate.

Beijing Foyou Pharma (601089.SH) has obtained the approval notice for the listing application of the raw material kelevoron.
HK Stock Market Move | MMG(01208) closing price rose more than 7%, operations at the Las Bambas mine area are stable, institutions raise full-year copper production guidance.

Tonghua Dongbao Pharmaceutical (600867.SH): Recombinant Human Insulin Injection receives foreign drug registration certificate.

Beijing Foyou Pharma (601089.SH) has obtained the approval notice for the listing application of the raw material kelevoron.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025


